Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-25-031218
Filing Date
2025-04-11
Accepted
2025-04-11 19:30:34
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 20099
2 JOINT FILING AGREEMENT, DATED APRIL 11, 2025, AMONG THE REPORTING PERSONS ea023805301ex1_soleus.htm EX-1 7778
3 LETTER DATED APRIL 11, 2025 FROM SOLEUS CAPITAL MANAGEMENT, L.P. TO THE ISSUER ea023805301ex2_soleus.htm EX-2 6277
4 GRAPHIC ex2_001.jpg GRAPHIC 3874
  Complete submission text file 0001213900-25-031218.txt   41350
Mailing Address 2015 PEEL STREET 5TH FLOOR MONTREAL A8 H3A 1T8
Business Address 2015 PEEL STREET 5TH FLOOR MONTREAL A8 H3A 1T8 514-336-7800
Theratechnologies Inc. (Subject) CIK: 0001512717 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 1130
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-86385 | Film No.: 25833969
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

EIN.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A